^
Association details:
| Biomarker: | KIAA1549-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Torisel (temsirolimus) (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome
Excerpt:
A malignant spindle cell tumor (Case 50) of the chest wall treated as a soft tissue sarcoma that featured a KIAA1549‐BRAF fusion (KIAA1549 exons 1–15–BRAF exons 9–18) showing pre‐ and post‐treatment CT scan images featuring tumor response to treatment with bevacizumab, temsirolimus and sorafenib.
DOI:
10.1038/nm.4092
